Recombinant Human RAB5A protein, His & T7-tagged

• Cat.No.: RAB5A-1770H
• Product Overview: Recombinant Human RAB5A aa. (Met1~Ser214 (Accession # P20339)) fused with N-terminal His & T7 tag was produced in E. coli cells.

Specification

• Source: E. coli
• Species: Human
• Tag: His & T7
• Form: Freeze-dried powder
• Molecular Mass: 31kDa as determined by SDS-PAGE reducing conditions.
• Protein length: Met1~Ser214 (Accession # P20339)
• Endotoxin: <1.0EU per 1ug (determined by the LAL method)
• Purity: >95%
• Applications: SDS-PAGE; WB; ELISA; IP.
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Storage buffer: Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl.
• Reconstitution: Reconstitute in sterile PBS, pH7.2-pH7.4.
• Isoelectric Point: 8.3

Gene Information

• Gene Name: RAB5A RAB5A, member RAS oncogene family [ Homo sapiens (human) ]
• Official Symbol: RAB5A
• Synonyms: RAB5A; RAB5A, member RAS oncogene family; RAB5; ras-related protein Rab-5A; RAS-associated protein RAB5A
• Gene ID: 5868
• mRNA Refseq: NM_001292048.1
• Protein Refseq: NP_001278977.1
• UniProt ID: P20339

Reviews

09/12/2021

If researchers require specific variants or modifications of RAB5A protein, the manufacturer can work with them to provide customized products tailored to their needs.

04/11/2020

Their expertise can help troubleshoot problems, suggest alternative approaches, or provide recommendations for optimizing experimental protocols.

06/17/2018

This level of support saves researchers time and resources, enabling them to focus on the scientific aspects of their work and accelerate the overall progress of their studies.

Q&As

Can targeting RAB5A be a therapeutic approach in cancer treatment?

Research suggests that modulating RAB5A activity may be a viable therapeutic strategy in cancer treatment.

How is RAB5A implicated in clinical applications?

RAB5A is associated with various cellular processes, and its dysregulation has been linked to several diseases.

How does RAB5A contribute to neurodegenerative diseases?

RAB5A dysfunction has been implicated in neurodegenerative diseases, affecting vesicle trafficking and cellular homeostasis in neurons.

Are there diagnostic implications of RAB5A in cancer?

Yes, altered levels of RAB5A expression can serve as potential diagnostic markers for certain cancers.

Are there ongoing clinical trials targeting RAB5A in neurodegenerative diseases?

Some clinical trials are exploring interventions targeting RAB5A to assess their potential in managing neurodegenerative conditions.